Phase III randomised trial
Why is this trial being carried out?
People who have had surgery to remove pancreatic cancer (for example, the Whipple’s operation) may be offered chemotherapy after their surgery. The aim is to reduce the chances of the cancer coming back. The chemotherapy drug most often used is gemcitabine (Gemzar®).
The APACT trial is looking at whether taking the chemotherapy drugs gemcitabine and nab-paclitaxel (Abraxane®) together after surgery is more likely to reduce the chances of the cancer coming back, compared to gemcitabine alone.
People who take part in this study will have either nab-paclitaxel and gemcitabine, or gemcitabine alone. They will have six cycles of chemotherapy treatment, and will have regular tests to check how well it is working. Each cycle lasts 28 days.
Who is the trial suitable for?
The APACT trial is suitable for people who have had surgery to remove their cancer. You will need to start the chemotherapy treatment within 12 weeks of having the surgery – you won’t be suitable for the trial is you had surgery more than 12 weeks ago. You will need to be fit enough for the chemotherapy treatment, and will have some tests to check this.
You won’t be able to take part in this trial if you:
have had radiotherapy or chemotherapy to treat pancreatic cancer before
have pancreatic cancer that has spread to other parts of your body (advanced or metastatic cancer), or if your cancer has come back after treatment
have neuroendocrine pancreatic cancer
have had any other type of cancer in the last five years (except cervical, womb or non melanoma skin cancer).
Speak to your doctor about whether this trial might be suitable for you.
The APACT trial is being carried out in centres across the world. In the UK, the following hospitals are taking part:
Addenbrookes Hospital, Cambridge
Glasgow Royal Infirmary and Beatson West of Scotland Cancer Centre
Weston Park Hospital, Sheffield.
Recruitment start date: March 2014
Recruitment end date: April 2016